Literature DB >> 21078952

Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.

Elijah Paintsil1, Ginger E Dutschman, Rong Hu, Susan P Grill, Chuan-Jen Wang, Wing Lam, Fang-Yong Li, Musie Ghebremichael, Veronika Northrup, Yung-Chi Cheng.   

Abstract

Individual variation in response to antiretroviral therapy is well-known, but it is not clear if demographic characteristics such as gender, age, and ethnicity are responsible for the variation. To optimize anti-HIV therapy and guide antiretroviral drug discovery, determinants that cause variable responses to therapy need to be evaluated. We investigated the determinants of intracellular concentrations of nucleoside analogs using peripheral blood mononuclear cells from 40 healthy donors. We observed individual differences in the concentrations of the intracellular nucleoside analogs; the mean concentrations of the triphosphate metabolite of ethynylstavudine (4'-Ed4T), zidovudine (AZT), and lamivudine (3TC) were 0.71 pmol/10(6) cells (minimum and maximum, 0.10 and 3.00 pmol/10(6) cells, respectively), 0.88 pmol/10(6) cells (minimum and maximum, 0.10 and 15.18 pmol/10(6) cells, respectively), and 1.70 pmol/10(6) cells (minimum and maximum, 0.20 and 7.73 pmol/10(6) cells, respectively). Gender and ethnicity had no effect on the concentration of 4'-Ed4T and 3TC metabolites. There was a trend for moderation of the concentrations of AZT metabolites by gender (P = 0.17 for gender·metabolite concentration). We observed variability in the activity and expression of cellular kinases. There was no statistically significant correlation between thymidine kinase 1 (TK-1) activity or expression and thymidine analog metabolite concentrations. The correlation between the activity of deoxycytidine kinase (dCK) and the 3TC monophosphate metabolite concentration showed a trend toward significance (P = 0.1). We observed an inverse correlation between the multidrug-resistant protein 2 (MRP2) expression index and the concentrations of AZT monophosphate, AZT triphosphate, and total AZT metabolites. Our findings suggest that the observed variation in clinical response to nucleoside analogs may be due partly to the individual differences in the intracellular concentrations, which in turn may be affected by the cellular kinases involved in the phosphorylation pathway and ATP-binding cassette (ABC) transport proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21078952      PMCID: PMC3028801          DOI: 10.1128/AAC.01303-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.

Authors:  Massimo Galli; Anna Lisa Ridolfo; Fulvio Adorni; Cristina Gervasoni; Laura Ravasio; Laura Corsico; Erika Gianelli; Manuela Piazza; Mauro Vaccarezza; Antonella d'Arminio Monforte; Mauro Moroni
Journal:  J Acquir Immune Defic Syndr       Date:  2002-01-01       Impact factor: 3.731

2.  Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

Authors:  A A Johnson; A S Ray; J Hanes; Z Suo; J M Colacino; K S Anderson; K A Johnson
Journal:  J Biol Chem       Date:  2001-08-28       Impact factor: 5.157

3.  Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.

Authors:  K A Lichtenstein; D J Ward; A C Moorman; K M Delaney; B Young; F J Palella; P H Rhodes; K C Wood; S D Holmberg
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

Review 4.  Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases.

Authors:  A R Van Rompay; M Johansson; A Karlsson
Journal:  Pharmacol Ther       Date:  2000 Aug-Sep       Impact factor: 12.310

5.  Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.

Authors:  J S Currier; C Spino; J Grimes; C B Wofsy; D A Katzenstein; M D Hughes; S M Hammer; D J Cotton
Journal:  J Acquir Immune Defic Syndr       Date:  2000-08-01       Impact factor: 3.731

Review 6.  Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.

Authors:  Patrick G Hoggard; David J Back
Journal:  Curr Opin Infect Dis       Date:  2002-02       Impact factor: 4.915

7.  Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.

Authors:  Jeff A Sloan; Richard M Goldberg; Daniel J Sargent; Delfino Vargas-Chanes; Suresh Nair; Steven S Cha; Paul J Novotny; Michael A Poon; Michael J O'Connell; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

8.  Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children.

Authors:  Daniel L Tuttle; Cynthia B Anders; M Janette Aquino-De Jesus; Paul P Poole; Susanna L Lamers; Daniel R Briggs; Steven M Pomeroy; Louis Alexander; Keith W C Peden; Warren A Andiman; John W Sleasman; Maureen M Goodenow
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-20       Impact factor: 2.205

9.  Oral immunization with a Salmonella enterica serovar typhi vaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans.

Authors:  B Samuel Lundin; Camilla Johansson; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

Authors:  Graeme J Moyle; Debasis Datta; Sundhiya Mandalia; John Morlese; David Asboe; Brian G Gazzard
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

View more
  8 in total

1.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

2.  Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.

Authors:  Joseph E Rower; Amie Meditz; Edward M Gardner; Kenneth Lichtenstein; Julie Predhomme; Lane R Bushman; Brandon Klein; Jia-Hua Zheng; Samantha Mawhinney; Peter L Anderson
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.

Authors:  N Jung; C Lehmann; A Rubbert; E Schömig; G Fätkenheuer; P Hartmann; D Taubert
Journal:  Infection       Date:  2012-08-09       Impact factor: 3.553

4.  Modulation of the pentose phosphate pathway alters phase I metabolism of testosterone and dextromethorphan in HepG2 cells.

Authors:  Wen-jing Xiao; Ting Ma; Chun Ge; Wen-juan Xia; Yong Mao; Run-bin Sun; Xiao-yi Yu; Ji-ye Aa; Guang-ji Wang
Journal:  Acta Pharmacol Sin       Date:  2015-01-26       Impact factor: 6.150

5.  Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line.

Authors:  Min Li; Anuoluwapo Sopeyin; Elijah Paintsil
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

6.  Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.

Authors:  M M Prokofjeva; P V Spirin; D V Yanvarev; A V Ivanov; M S Novikov; O A Stepanov; M B Gottikh; S N Kochetkov; B Fehse; C Stocking; V S Prassolov
Journal:  Acta Naturae       Date:  2011-10       Impact factor: 1.845

7.  Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals.

Authors:  Anuoluwapo Sopeyin; Lei Zhou; Min Li; Lydia Barakat; Elijah Paintsil
Journal:  PLoS One       Date:  2019-12-17       Impact factor: 3.240

8.  The apoptotic effects of toosendanin are partially mediated by activation of deoxycytidine kinase in HL-60 cells.

Authors:  Jianming Ju; Zhichao Qi; Xueting Cai; Peng Cao; Yan Huang; Shuzhen Wang; Nan Liu; Yijun Chen
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.